Location Trial Status:

= Fully recruited

= Recruiting

= Not yet recruiting

= Enrolling by invitation


Sarepta 51 (Young)

Study of Eteplirsen in Young Patients with DMD Amenable to Exon 51 Skipping

Hub Summary

This phase 2 open-label study is designed to determine the safety and efficacy of eteplirsen in young patients with DMD. Etepliresen (EXONDYS 51®) is an exon-skipping drug designed to treat patients with DMD amenable to exon 51 skipping. This study will enroll young males between the ages of 6 months and 4 years.

Study Number: NCT03218995

Description by Sarepta Therapeutics, Inc.

This is a multicenter, open-label, dose-escalation study to evaluate the safety, tolerability, PK, and efficacy of once-weekly IV infusions of eteplirsen in approximately 12 male patients, ages 6 months to 48 months (inclusive), who have genotypically confirmed DMD with a deletion mutation amenable to exon 51 skipping.

 
Primary Outcome Measures

  • Incidence of adverse events [ Time Frame: Up to 96 Weeks ]
  • Abnormal changes from baseline or clinically significant worsening of clinical safety laboratory abnormalities (hematology, chemistry, coagulation, and urinalysis) [ Time Frame: Change from Baseline ]
  • Abnormal changes from baseline or worsening of vital signs [ Time Frame: Change from Baseline ]
  • Abnormal changes from baseline or worsening of physical examination findings [ Time Frame: Change from Baseline ]
  • Abnormal changes from baseline or clinically significant worsening of electrocardiogram (ECG) and echocardiogram (ECHO) [ Time Frame: Change from Baseline ]

 
Secondary Outcome Measures

  • Maximum plasma concentration [ Time Frame: 24 Weeks ]
  • Time of Cmax (Tmax) [ Time Frame: 24 Weeks ]
  • Area under the concentration-time curve (AUC) [ Time Frame: 24 Weeks ]
  • Apparent volume of distribution at steady state (Vss) [ Time Frame: 24 Weeks ]
  • Clearance (CL) [ Time Frame: 24 Weeks ]
  • Elimination half-life (t½) [ Time Frame: 24 Weeks ]
  • Amount of drug eliminated in urine (Ae%) [ Time Frame: 24 Weeks ]

 
Can I take part?

 
Inclusion Criteria

  • Male between 6 months to 48 months of age (inclusive): 
    • Cohort 1: Age 24-48 months (enrolment closed)
    • Cohort 2: Age 6-24 months (currently enrolling)
  • Diagnosis of DMD with a deletion mutation amenable to exon 51 skipping
  • Parent(s) or legal guardian(s) who is willing to provide written informed consent

 
Exclusion Criteria

  • Received treatment that might have an effect on muscle strength or function within 12 weeks prior to dosing
  • Received previous or current treatment with any experimental treatment
  • Clinically significant illness other than DMD
  • Clinically significant laboratory abnormality
  • Any other condition that could interfere with the patient's participation
 
Download PDF
Overall Trial Status
Recruiting
UK Locations
Trial Sponsor
Sarepta Therapeutics, Inc.
Age
6 months to 4 years
Mutation Specific
Mutation specific therapies, Must be amenable to exon 51 skipping
Muscle Biopsy
No Muscle Biopsy Required
MRI
No
Phase
2
Length Of Participation
12 weeks
Therapeutic Category
Exon-skipping

We have placed cookies on your computer to help make this website better. For more information please click here

By continuing to use this site or closing this panel, we'll assume you're OK to continue. You can view our full privacy policy here